RRR schreef op 21 juni 2014 15:07:
Kosten?... Wat denk je bv hiervan...
The cost per patient of running Phase 3 clinical studies of new pharmaceuticals exceeds $26,000, on average, according to a new benchmarking report, "Clinical Operations: Accelerating Trials, Allocating Resources and Measuring Performance" (http://www.ClinicalTrialBenchmarking.com), published by business intelligence firm Cutting Edge Information. The company surveyed dozens of leading pharmaceutical and biotech companies about their clinical development spending, staffing, and performance measurement practices. Survey data reveal that Phase 3 studies are the most costly as measured on a per-patient basis. Phase 2 trials are comparatively cheaper, with the average per-patient cost falling just over $19,300 per patient. Phase 1 trials, which test drugs' safety on a fraction of the number of patients tested in Phase 3 trials, are even less expensive at nearly $15,700 per patient
www.fda.gov/drugs/resourcesforyou/con...En afhankelijk van welke phase... Zijn dat er nogal wat...
En... Stel voor en komt een 'post aproval phase' ... Kan ook nog he...
'In Phase 4 trials, postmarketing studies delineate additional information, including the treatment's risks, benefits, and optimal use.'